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The debate about the role of the use of corticosteroids (CS)
s treatment support in patients with pneumonia due to novel
oronavirus (2019-nCoV) is currently ongoing with several differ-
nt opinion and a substantial lack of evidence. About this, we read
ith great interest the letter by Fang et al. recently published in
his journal. 1 Generalising available data about other viral or bac-
erial pneumonia is not entirely applicable to nCoV infection and
 detailed examination is requested. A previous reported summary
f clinical evidence about the role of CS in SARS-CoV, MERS-CoV
nd Influenza virus showed all negative effects related to CS ad-
inistration: delayed clearance of viral RNA from respiratory tract
r blood, onset of psychosis, diabetes, avascular necrosis, increased
ortality. 2 However, the report by Stockman et al. is not a meta-
nalysis but only a systematic review with a qualitative inclusionFig. 1. Relationship between timing of CS administration an
ttps://doi.org/10.1016/j.jinf.2020.08.001 
163-4453/© 2020 The British Infection Association. Published by Elsevier Ltd. All rights rriteria of the studies and does not provide a quantitative effect
ize of reported factors. On the other side, a meta-analysis reported
 reduction of mortality and rate of mechanical ventilation in pa-
ients with severe community-acquired pneumonia (SCAP) 3 but in
his analysis the higher heterogeneity was observed and in the
ubgroup evaluation of other pathogen identified only 31 (9.4%)
ere influenza virus A or B, while 45 (13.6%) were Legionella
pecies. The low number of viral pathogens and the subgroup anal-
sis with other bacterial pathogens (in particular Legionella, with
ome evidences of harm from CS use) does not provide in our
pinion a solid evidence of benefit from CS use. A 2019 meta-
nalysis about the effect of CS in influenza pneumonia described
he negative impact on mortality, days of hospitalization, days in
ntensive care unit (ICU) and secondary bacterial and fungal infec-
ions; in all these outcomes, however, the reported heterogeneity
as higher (except for the days in ICU, but with only two studies
ncluded) and the only subgroup analysis performed was between
1N1 vs other viral infection; is likely that other subgroup analysis
hould be assessed such as according age, comorbidities, severityd mortality in patients with 2019-nCoV pneumonia. 
eserved. 
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of pneumonia, need of non-invasive ventilation and others. Despite
some data supporting the benefit of the use of CS in viral pneu-
monia, 4 a recent expert consensus statement focused the atten-
tion on the caution of this therapeutic support in the 2019-nCoV
pneumonia, especially in critically ill patients with underliyng dis-
eases and major risk of other bacterial or fungal infection. 5 Two
major issues, in our opinion, should be deepened in the approach
of this discussion: first, the dose and the type of CS used can play
a decisive role on the outcome in 2019-nCoV pneumonia: low or
moderate dose of methylprednisolone were considered useful in
influenza viral pneumonia, while in acute lung injury, acute res-
piratory distress syndrome (ARDS) or septic shock higher doses of
both methylprednisolone and dexamethasone were employed with
conflicting results. 6 Second, the timing of the CS use maybe a piv-
otal role in this topic because an early administration in patients
without severe hypoxaemic respiratory failure before the ARDS de-
velopment could prevent the onset of cytokine-related lung injury,
while a late use of CS in subjects with advanced lung damage and
critical condition can lead to bacterial infections, delayed clearance
of virus and other unfavorable outcomes. Unfortunately, the tim-
ing data was not reported in the majority of the available studies
and consequently the results may be affected by an important bias.
In the study by Wu et al. 7 a reduction of the risk of death was
observed in patients with ARDS treated with methylprednisolone
(HR = 0.38, p = 0.003): 50 of 84 patients with ARDS received CS
treatment (59.5%) but no informations on the dose and duration of
this treatment were reported; the Authors conclude that this find-
ing should be evaluated with caution due to low size of patients
and a possible risk of bias. 
In a recent paper by Horby et al. 8 an encouraging evidence
of effectiveness of the use of dexamethasone (at the dose of
6 mg/daily for up to 10 days) was reported in a large random-
ized study; a lower mortality rate was observed in patients receiv-
ing dexamethasone than in other subjects without glucocorticoids
treatment; in particular, this result was more evident in patients
with mechanical ventilation or respiratory support, while no clear
benefit were observed in patients without need of oxygen. 
In this context, we reported our experience on the CS use
in the first 149 patients admitted in our unit of infectious dis-
eases affected by SARS-CoV-2 infection. Despite the use of CS does
not seem related to a reduction of mortality rate (OR = 0.857;
95%CI = 0.377–1.947; p = 0.703), we found a significant lower
mortality in patients without ARDS who received an early CSdministration (median 1.0 days after hospital admission) in com-
arison to late CS treatment (median 3.1 days) (OR = 0.224;
5%CI = 0.127–3.449; p = 0.018) ( Fig. 1 ). This finding could mean
 positive effect of the CS supportive timing therapy before the
RDS development, but the low number and higher heterogeneity
f these patients require further confirmations. 
In conclusion, at this time we have some evidence about a pos-
tive effect of CS support; further studies are required to better un-
erstand the proper use, dose and timing of this treatment during
019-nCoV pneumonia. 
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